Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
J Seismol ; 21(4): 857-868, 2017.
Article in English | MEDLINE | ID: mdl-28729809

ABSTRACT

The receiver function (RF) technique is a well-established method to investigate the crustal and upper mantle structures based on three-component seismograms of teleseismic events. In the present study, we propose a modified automatic procedure to determine the back azimuth and polarization angles of a teleseismic event based on the RF technique. The method is tested for the recording of 3 permanent and 3 temporary broadband seismic stations located in the vicinity of Poland. Additionally, the analysis of Rayleigh wave polarization is conducted to show that the new procedure is not sensitive to incorrect seismometer orientation. The synthetic modelling of RF by a modified ray-tracing method for 2.5D models beneath each seismic station down to a depth of 60 km is performed to show the effectiveness of the proposed method in the calculation of RF for a complex structure with dipping layers.

2.
Endoscopy ; 45(2): 142-50, 2013.
Article in English | MEDLINE | ID: mdl-23335011

ABSTRACT

BACKGROUND AND AIM: This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It addresses the choice amongst regimens available for cleansing the colon in preparation for colonoscopy. METHODS: This Guideline is based on a targeted literature search to evaluate the evidence supporting the use of bowel preparation for colonoscopy. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was adopted to define the strength of recommendation and the quality of evidence. RESULTS: The main recommendations are as follows. (1) The ESGE recommends a low-fiber diet on the day preceding colonoscopy (weak recommendation, moderate quality evidence). (2) The ESGE recommends a split regimen of 4 L of polyethylene glycol (PEG) solution (or a same-day regimen in the case of afternoon colonoscopy) for routine bowel preparation. A split regimen (or same-day regimen in the case of afternoon colonoscopy) of 2 L PEG plus ascorbate or of sodium picosulphate plus magnesium citrate may be valid alternatives, in particular for elective outpatient colonoscopy (strong recommendation, high quality evidence). In patients with renal failure, PEG is the only recommended bowel preparation. The delay between the last dose of bowel preparation and colonoscopy should be minimized and no longer than 4 hours (strong recommendation, moderate quality evidence). (3) The ESGE advises against the routine use of sodium phosphate for bowel preparation because of safety concerns (strong recommendation, low quality evidence).


Subject(s)
Cathartics/administration & dosage , Colonoscopy/methods , Laxatives/administration & dosage , Humans
3.
Colorectal Dis ; 15(1): e48-55, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23006660

ABSTRACT

AIM: Chronic radiation proctitis is a long-term complication of radiation therapy for pelvic malignancy. The aim of this study was to compare the efficacy and safety of two treatment regimens, sucralfate or placebo, following argon plasma coagulation (APC) for chronic haemorrhagic radiation proctitis. METHOD: A single-centre, randomized, placebo-controlled, double-blind study was performed on patients with haemorrhagic chronic radiation proctitis after irradiation for prostate, uterine, cervical, rectal or vaginal cancer. All patients received APC, and were then randomized to oral sucralfate (6 g twice a day) or placebo treatment for 4 weeks. APC was repeated every 8 weeks if necessary after the first session. Patients were graded clinically and endoscopically according to the Chutkan and Gilinski scales before and at 8 and 16 weeks after initial APC treatment (1.5-2 l/min, 25-40 W) and after 52 weeks (clinical only). RESULTS: Of 122 patients, 117 completed the entire protocol, with 57/60 in the sucralfate group and 60/62 in the placebo group. At baseline there were no significant differences between the sucralfate and placebo groups. At 1 year, a significant improvement in the clinical scale in both groups occurred compared with baseline. After 16 weeks, the median overall clinical severity scores fell from 4 to 2 points and the median bleeding score from 2 to 0 in both groups. CONCLUSION: APC is safe and effective for the management of chronic radiation proctitis. Additional sucralfate treatment did not influence the clinical or endoscopic outcome.


Subject(s)
Anti-Ulcer Agents/therapeutic use , Argon Plasma Coagulation , Gastrointestinal Hemorrhage/therapy , Proctitis/therapy , Radiation Injuries/therapy , Sucralfate/therapeutic use , Aged , Chronic Disease , Double-Blind Method , Female , Gastrointestinal Hemorrhage/etiology , Humans , Male , Middle Aged , Proctitis/etiology , Radiation Injuries/etiology , Radiotherapy/adverse effects , Severity of Illness Index
4.
Br J Cancer ; 107(8): 1433-41, 2012 Oct 09.
Article in English | MEDLINE | ID: mdl-22929880

ABSTRACT

BACKGROUND: Prognosis of localised gastrointestinal stromal tumour (GIST) is heterogeneous, notably for patients with AFIP intermediate or high risk of relapse, who are candidates to adjuvant imatinib. We hypothesised that gene expression profiles might improve the prognostication and help to refine the indications for imatinib. METHODS: We collected gene expression and histoclinical data of 146 pre-treatment localised GIST samples treated with surgery alone. We searched for a gene expression signature (GES) predictive for relapse-free survival (RFS) and compared its performances to that of three published prognostic proliferation-based GES (Genomic Grade Index (GGI), 16-Kinase, and CINSARC) and AFIP classification. We also analysed a data set from 28 patients with advanced GIST treated with neo-adjuvant imatinib. RESULTS: We identified a 275-gene GES (gene expression signature) predictive of RFS in a learning set and validated its robustness in an independent set. However, the GGI outperformed its prognostic performances, and those of the two other signatures and the AFIP intermediate-risk classification in two independent tests sets in uni- and multivariate analyses. Importantly, GGI could split the AFIP intermediate/high-risk samples into two groups with different RFS. Genomic Grade Index 'high-risk' tumours were more proliferative and genetically unstable than 'low-risk' tumours, and more sensitive to imatinib. CONCLUSION: GGI refines the prediction of RFS in localised GIST and might help tailor adjuvant imatinib.


Subject(s)
Gastrointestinal Stromal Tumors/genetics , Antineoplastic Agents/therapeutic use , Benzamides , Female , Gastrointestinal Stromal Tumors/drug therapy , Gastrointestinal Stromal Tumors/surgery , Gene Expression Profiling , Humans , Imatinib Mesylate , Male , Middle Aged , Oligonucleotide Array Sequence Analysis , Piperazines/therapeutic use , Prognosis , Pyrimidines/therapeutic use , Treatment Outcome
5.
Endoscopy ; 44(4): 394-8, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22370702
6.
Endoscopy ; 44(2): 190-206, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22180307

ABSTRACT

This article is the second of a two-part publication that expresses the current view of the European Society of Gastrointestinal Endoscopy (ESGE) about endoscopic ultrasound (EUS)-guided sampling, including EUS-guided fine needle aspiration (EUS-FNA) and EUS-guided Trucut biopsy. The first part (the Clinical Guideline) focused on the results obtained with EUS-guided sampling, and the role of this technique in patient management, and made recommendations on circumstances that warrant its use. The current Technical Guideline discusses issues related to learning, techniques, and complications of EUS-guided sampling, and to processing of specimens. Technical issues related to maximizing the diagnostic yield (e.g., rapid on-site cytopathological evaluation, needle diameter, microcore isolation for histopathological examination, and adequate number of needle passes) are discussed and recommendations are made for various settings, including solid and cystic pancreatic lesions, submucosal tumors, and lymph nodes. The target readership for the Clinical Guideline mostly includes gastroenterologists, oncologists, internists, and surgeons while the Technical Guideline should be most useful to endoscopists who perform EUS-guided sampling. A two-page executive summary of evidence statements and recommendations is provided.


Subject(s)
Biopsy/methods , Endoscopy, Gastrointestinal , Endosonography , Gastrointestinal Diseases/pathology , Ultrasonography, Interventional , Biopsy/adverse effects , Education, Medical, Continuing , Endoscopy, Gastrointestinal/adverse effects , Endoscopy, Gastrointestinal/education , Endoscopy, Gastrointestinal/methods , Endosonography/adverse effects , Endosonography/methods , Europe , Gastroenterology/education , Gastroenterology/methods , Humans , Postoperative Complications/prevention & control , Specimen Handling/methods , Ultrasonography, Interventional/adverse effects , Ultrasonography, Interventional/methods
7.
Endoscopy ; 43(10): 897-912, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21842456

ABSTRACT

This article is part of a combined publication that expresses the current view of the European Society of Gastrointestinal Endoscopy (ESGE) about endoscopic ultrasound (EUS)-guided sampling in gastroenterology, including EUS-guided fine needle aspiration (EUS-FNA) and EUS-guided trucut biopsy (EUS-TCB), of submucosal tumors, diffuse esophageal/gastric wall thickening, pancreatic solid masses and cystic-appearing lesions, mediastinal lesions unrelated to lung or esophageal cancer, cancer of the esophagus, stomach, and rectum, lymph nodes of unknown origin, adrenal gland masses, and focal liver lesions. False-positive cytopathological results and needle tract seeding are also discussed. The present Clinical Guideline describes the results of EUS-guided sampling in the different clinical settings, considers the role of this technique in patient management, and makes recommendations on circumstances that warrant its use. A two-page executive summary of evidence statements and recommendations is provided. A separate Technical Guideline describes the general technique of EUS-guided sampling, particular techniques to maximize the diagnostic yield depending on the nature of the target lesion, and sample processing. The target readership for the Clinical Guideline mostly includes gastroenterologists, oncologists, internists, and surgeons while the Technical Guideline should be most useful to endoscopists who perform EUS-guided sampling.


Subject(s)
Adrenal Gland Neoplasms/pathology , Biopsy, Fine-Needle/standards , Digestive System Neoplasms/diagnostic imaging , Digestive System Neoplasms/pathology , Mediastinal Neoplasms/pathology , Ultrasonography, Interventional/standards , Adrenal Gland Neoplasms/diagnostic imaging , Esophageal Diseases/diagnostic imaging , Esophageal Diseases/pathology , False Positive Reactions , Humans , Lymph Nodes/diagnostic imaging , Lymph Nodes/pathology , Mediastinal Neoplasms/diagnostic imaging , Pancreatic Cyst/diagnostic imaging , Pancreatic Cyst/pathology , Stomach Diseases/diagnostic imaging , Stomach Diseases/pathology
10.
Endoscopy ; 42(1): 68-72, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20066593
11.
Article in English | MEDLINE | ID: mdl-19744630

ABSTRACT

Numerous studies conducted over the last 25 years provide evidence on the high diagnostic accuracy and important role of endoscopic ultrasonography (EUS) in staging oesophageal and gastric carcinoma. This extensive research was recently subjected to metaanalyses, condensing our knowledge on EUS performance and facilitating its comparison with competing methods. It is, however, important to realise that the management of oesophageal and gastric carcinoma is evolving and so are staging algorithms, setting new challenges for EUS and re-defining its position. Restaging after neoadjuvant treatment and precise assessment of early carcinoma before endoscopic treatment are areas of growing interest, but the role of EUS in these settings is rather limited. Rapidly developing cross-sectional imaging has the potential to challenge the position of EUS as the most accurate method in loco-regional staging. On the other hand, EUS guided fine-needle aspiration offers the unique opportunity to obtain cytological confirmation of lymph node metastases, with future potential for molecular staging.


Subject(s)
Endoscopy, Gastrointestinal , Endosonography , Esophageal Neoplasms/diagnostic imaging , Intestinal Neoplasms/diagnostic imaging , Stomach Neoplasms/diagnostic imaging , Biopsy, Fine-Needle , Esophageal Neoplasms/secondary , Esophageal Neoplasms/therapy , Esophagogastric Junction/diagnostic imaging , Humans , Intestinal Neoplasms/secondary , Intestinal Neoplasms/therapy , Lymphatic Metastasis , Neoplasm Staging , Predictive Value of Tests , Stomach Neoplasms/secondary , Stomach Neoplasms/therapy , Tomography, X-Ray Computed
12.
Endoscopy ; 41(4): 329-34, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19340737

ABSTRACT

BACKGROUND AND STUDY AIMS: Endoscopic-ultrasound-guided trucut needle biopsy (EUS-TCB) has not been adequately evaluated in patients with submucosal tumors (SMTs). PATIENTS AND METHODS: This prospective, uncontrolled study involving 49 consecutive patients with hypoechoic gastric SMTs (> or = 20 mm) evaluated diagnostic yield and 30-day morbidity of EUS-TCB, factors related to the success of EUS-TCB, and agreement between EUS-TCB and the surgical pathology diagnosis. Seventy-three percent of tumors were gastrointestinal stromal tumors (GIST). RESULTS: Tumor tissue adequate for diagnosis was obtained by EUS-TCB in 31 patients (63 %; 95 %CI 49 % to 75 %). In the remaining cases, EUS-TCB provided no tissue (n = 11) or an insufficient amount (n = 7). Logistic regression analysis showed that tumor location on the lesser curvature of the stomach was the only independent predictor of obtaining diagnostic material [odds ratio (OR) 7.4; 95 %CI 1.9 to 28; P = 0.004]. The experience of the endosonographer, the size of the tumor, and the location of the tumor relative to the long axis of the stomach were not related to the success of the biopsy. Agreement between EUS-TCB and surgical pathology specimens in respect of the diagnosis and CD117 status was high (0.9, standard error 0.31; and 0.95, standard error 0.16, respectively); however, there was no correlation between the mitotic index as determined on EUS-TCB and that determined on the surgical pathology specimen (correlation coefficient, 0.08). There were two severe septic complications in 52 procedures (3.9 %; 95 %CI 0.3 % to 14 %). CONCLUSIONS: The diagnostic yield of EUS-TCB in patients with gastric SMTs was moderate. Tissue samples were too small to reliably determine the mitotic index. Antibiotic prophylaxis should be considered because of possible septic complications.


Subject(s)
Biopsy, Needle/methods , Gastric Mucosa/diagnostic imaging , Gastric Mucosa/pathology , Gastroscopy/methods , Stomach Neoplasms/diagnostic imaging , Stomach Neoplasms/pathology , Abscess/etiology , Aged , Biopsy, Needle/adverse effects , Endosonography , Female , Gastroscopy/adverse effects , Humans , Logistic Models , Male , Middle Aged , Mitotic Index , Odds Ratio , Predictive Value of Tests , Prospective Studies , Sepsis/etiology , Streptococcal Infections/etiology
15.
Endoscopy ; 39(4): 296-303, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17427065

ABSTRACT

BACKGROUND AND STUDY AIMS: Diagnostic endoscopic retrograde cholangiography (ERC) is being replaced by endoscopic ultrasonography (EUS) in patients with suspected bile duct stones. The assumption that such an approach is advantageous, however, has never been tested in a randomized trial. PATIENTS AND METHODS: 100 patients with intermediate probability of bile duct stones were randomly allocated to EUS or ERC. Two patients in the ERC group were excluded; the remaining 98 patients received the allocated intervention and were entered into the analysis (EUS, 50 patients; ERC, 48 patients). Detected stones were removed endoscopically; patients without stones were followed for 1 year. The primary end point was the proportion of patients with a negative outcome, related to either endoscopic procedures (complications) or to false-negative diagnosis of stones. Investigators assessing the negative outcomes were not blinded to group assignment. The secondary end point was the total number of endoscopic procedures (EUS and ERC) performed in each group to diagnose and treat stones. RESULTS: Bile duct stone prevalence was 28% and 25% in the EUS and ERC groups, respectively (P > 0.05). In the EUS group, 71 endoscopic procedures were performed, and 63 in the ERC group (mean per patient, 1.42 +/- 0.76, and 1.31 +/- 0.55, respectively; P > 0.05). In the EUS group, these included 49 successful and one failed initial EUS, 15 ERCs for bile duct stone treatment, and six procedures required during follow-up. In the ERC group there were 36 successful and 12 failed initial ERCs, 13 repeat procedures (EUS or ERC) performed after failed or equivocal initial ERC, and two procedures during follow-up. Five patients in the EUS group (10%, 95% CI 4-22) and 19 patients in the ERC group (40%, 95% CI 27-54) experienced a negative outcome (P < 0.001). No difference was observed when only moderate to severe complications were considered (6%, 95% CI 1-17, and 10%, 95% CI 4-23, respectively). CONCLUSIONS: In patients with intermediate probability of bile duct stones, the management strategy based on EUS (with selective ERC in patients with confirmed stones) is safer and not associated with an excess of endoscopic procedures compared with a strategy based on ERC alone.


Subject(s)
Cholangiopancreatography, Endoscopic Retrograde , Endosonography , Gallstones/diagnosis , Abdominal Pain/etiology , Common Bile Duct/diagnostic imaging , Common Bile Duct/pathology , Dilatation, Pathologic , Gallstones/complications , Gallstones/diagnostic imaging , Gallstones/epidemiology , Gallstones/surgery , Humans , Pancreatic Neoplasms/epidemiology , Prospective Studies , Sphincterotomy, Endoscopic , Treatment Outcome
16.
Adv Med Sci ; 52: 296-300, 2007.
Article in English | MEDLINE | ID: mdl-18217437

ABSTRACT

Nodular lymphoid hyperplasia is uncommon in adult patients. Associated diseases are common variable immunodeficiency (CVI) and lymphoid tissue malignancies. In this case report we focus on clinical presentation and differential diagnosis of diffuse nodular lymphoid hyperplasia of the gastrointestinal tract coexisting with selective immunoglobulin A deficiency and sarcoid-like syndrome.


Subject(s)
Castleman Disease/diagnosis , Gastrointestinal Tract/pathology , IgA Deficiency/diagnosis , Sarcoidosis/diagnosis , Adult , Castleman Disease/complications , Humans , Hyperplasia , IgA Deficiency/complications , Immunoglobulin A/metabolism , Immunoglobulin E/metabolism , Immunoglobulin G/metabolism , Immunoglobulin M/metabolism , Immunohistochemistry/methods , Male , Sarcoidosis/complications , Syndrome , Tomography, X-Ray Computed/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...